

**ANTISENSE MODULATION OF FAS MEDIATED SIGNALING****INTRODUCTION**

This application is a continuation of U.S. Serial No. 09/802,669 filed March 9, 2001 which is a continuation-in-part of U.S. Serial No. 09/665,615 filed September 18, 2000, which is a continuation-in-part of U.S. Serial No. 09/290,640 filed April 12, 1999.

**FIELD OF THE INVENTION**

This invention relates to compositions and methods for modulating expression of the human Fas, FasL and Fap-1 genes, which encode proteins involved in Fas mediated signal transduction and are implicated in disease. This invention is also directed to methods for inhibiting Fas, FasL or Fap-1-mediated signal transduction; these methods can be used diagnostically or therapeutically. Furthermore, this invention is directed to treatment of conditions associated with expression of the human Fas, FasL or Fap-1 genes.

**BACKGROUND OF THE INVENTION**

The Fas ligand (FasL, also CD95L or Apo-1L) belongs to the tumor necrosis factor (TNF) family. It associates with the Fas receptor (Fas, also CD95 or Apo-1). Both function primarily as membrane-bound cell-surface proteins. The interaction between Fas and FasL is a key regulator of apoptosis within the immune system. Binding of FasL by Fas triggers apoptosis. Since both Fas and FasL are typically membrane-bound, cells expressing either Fas or FasL generally must come into contact with cells expressing the other in order to induce cell death (Rowe, P.M., *Lancet*,

1996, 347, 1398). Under normal conditions, expression of the FasL is generally limited to activated T cells and macrophages. Fas is expressed in a variety of lymphoid and non-lymphoid cells including thymus, liver, heart and  
5 kidney (Watanabe-Fukunaga, R., et al., J. Immunol., 1992, 148, 1274-1279).

Expression of FasL is involved in a number of cancers, including lymphomas, melanoma (Hahne, M., et al., Science, 1996, 274, 1363-1366), colon, hepatic and lung  
10 carcinomas and astrocytomas (Saas, P., et al., J. Clin. Invest., 1997, 99, 1173-1178). It is thought that FasL expression by tumor cells is a mechanism by which they escape killing by the immune system and instead enables them to kill immune cells possessing Fas receptor on their  
15 surfaces (Walker, P.R., et al., J. Immunol., 1997, 158, 4521-4524).

Fas and FasL are also involved in other diseases, including autoimmune and inflammatory diseases. These include Hashimoto's thyroiditis (Giordano, C., et al.,  
20 Science, 1997, 275, 1189-1192), hepatitis (Kondo, T., et al., Nat. Med., 1997, 3, 409-413), diabetes (Chervonsky, A.V., et al., Cell, 1997, 89, 17-24), myasthenia gravis (Moulian, N., et al., Blood, 1997, 89, 3287-3295), ulcerative colitis (Strater, J., et al., Gastroenterology,  
25 1997, 113, 160-167), autoimmune gastritis (Nishio, A., et al., Gastroenterology 1996, 111, 959-967), Sjogren's syndrome (Kong, L., et al., Arthritis Rheum., 1997, 40, 87-97) and HIV infection (Sieg, S., et al., Proc. Natl. Acad. Sci (USA), 1997, 94, 5860-5865).

30 Fap-1 (Fas associated protein 1 or protein tyrosine phosphatase (PTP-BAS, type 1)) is a tyrosine phosphatase that binds with a negative regulatory element of Fas (Sato, T., et al., Science, 1995, 268, 411-415). It also is an inhibitor of Fas-mediated apoptosis and an important

component of Fas mediated signaling. The presence of Fap-1 in tumor cell lines also correlated with resistance to Fas antibody. Takahashi, M. et al. (*Gan To Kagaku Ryoho*, **1997**, 24, 222-228) found that Fap-1 was expressed in many colon  
5 cancer cell lines, but not in normal colon cells.

Several approaches have been used to study the interaction between Fas and FasL and could potentially be used for therapeutic purposes. One way to disrupt the balance (altered or normal) between Fas and FasL is to  
10 provide additional amounts of one of them. This approach has been used with soluble Fas by Kondo, T., et al. (*Nature Med.*, **1997**, 3, 409-413) to prevent hepatitis in a transgenic mouse model and Cheng, J., et al. (*Science*, **1994**, 263, 1759-1762) to inhibit Fas-mediated apoptosis in  
15 systemic lupus erythematosus. Arai, H., et al. (*Proc. Natl. Acad. Sci. USA*, **1997**, 94, 13862-13867) used a somewhat different approach to increase FasL. An adenoviral expression vector containing FasL was used to infect tumor cells. The increased levels of FasL induced  
20 apoptosis and caused tumor regression.

Portions of these proteins could also be used. It was found that the three C-terminal amino acids of Fas were necessary and sufficient for binding to Fap-1 (Yanagisawa, J., et al., *J. Biol. Chem.*, **1997**, 272, 8539-8545).  
25 Introduction of this peptide into a colon cancer cell line induced Fas-mediated apoptosis.

Monoclonal antibodies to Fas have been used extensively to induce apoptosis. Anti-Fas antibodies resulted in tumor regression in B cell tumors (Trauth B.C.,  
30 et al., *Science*, **1989**, 245, 301-305), adult T-cell leukemia (Debatin, K.M., et al., *Lancet*, **1990**, 335, 497-500), gliomas (Weller, M., et al., *J. Clin. Invest.*, **1994**, 94, 954-964), and colorectal cancer (Meterissian, S.H., *Ann.*

*Surg. Oncol.*, **1997**, 4, 169-175). Antibodies to Fas also killed HIV infected cells (Kobayashi, N., et al., *Proc. Natl. Acad. Sci USA*, **1990**, 87, 9620-9624). Monoclonal antibodies have been used in combination with

- 5 chemotherapeutic drugs to overcome drug resistance (Morimoto, H., et al., *Cancer Res.*, **1993**, 53, 2591-2596), Nakamura, S., et al., *Anticancer Res.*, **1997**, 17, 173-179) and Wakahara, Y., et al., *Oncology*, **1997**, 54, 48-54).

- Chemical agents have been used to inhibit FasL  
10 expression (Yang, Y., et al., *J. Exp. Med.*, **1995**, 181, 1673-1682). Retinoic acid and corticosteroids inhibit the up-regulation of FasL.

- An antisense RNA approach, involving the antisense expression of a significant portion of a gene, has been  
15 used to modulate expression of Fas and Fap-1. Herr, I. et al. (*EMBO J.*, **1997**, 16, 6200-6208) expressed a 360 bp fragment of Fas in the antisense orientation to inhibit apoptosis. Freiss, G. et al. (*Mol. Endocrinol.*, **1998**, 12, 568-579) expressed a greater than 600 bp fragment of Fap-1  
20 to inhibit Fap-1 expression.

- Oligonucleotides have also been used to modulate expression of FasL. A bifunctional ribozyme targeted to both perforin and FasL was designed to treat graft-versus-host disease (Du, Z., et al., *Biochem. Biophys. Res. Commun.*, **1996** 226, 595-600). Antisense oligonucleotides  
25 have been used against both Fas and FasL. Yu, W. et al. (*Cancer Res.*, **1999**, 59, 953-961) used an oligonucleotide targeted to the translation initiation site of human Fas to reduce Fas mediated signaling in breast cancer cells. Lee,  
30 J., et al. (*Endocrinology*, **1997**, 138, 2081-2088) used an oligonucleotide targeted to the translation initiation region of rat FasL to show that Fas system regulates spermatogenesis. Turley, J.M., et al. (*Cancer Res.*, **1997**,

57, 881-890) used an oligonucleotide targeted to the translation initiation region of human FasL to show that the Fas system was involved in Vitamin E succinate mediated apoptosis of human breast cancer cells. O'Connell, J., et al. (*J. Exp. Med.*, **1996**, 184, 1075-1082) used a model involving Jurkat T cells and SW620, a colon cancer cell line. The presence of FasL on SW620 causes apoptosis of Jurkat cells which possess the Fas receptor. Antisense oligonucleotides to either the FasL on SW620 or Fas on Jurkat cells could prevent apoptosis of the Jurkat cells. Oligonucleotides were designed to target sequences toward the 3' end of the coding region.

There remains a long-felt need for improved compositions and methods for inhibiting Fas, FasL and Fap-1 gene expression.

#### SUMMARY OF THE INVENTION

The present invention provides antisense compounds, including antisense oligonucleotides, which are targeted to nucleic acids encoding Fas, FasL and Fap-1 and are capable of modulating Fas mediated signaling. The present invention also provides chimeric oligonucleotides targeted to nucleic acids encoding human Fas, FasL and Fap-1. The compounds and compositions of the invention are believed to be useful both diagnostically and therapeutically, and are believed to be particularly useful in the methods of the present invention. The present invention also comprises methods of modulating the Fas mediated signaling, in cells and tissues, using the antisense compounds of the invention. Methods of inhibiting Fas, FasL and Fap-1 expression are provided; these methods are believed to be useful both therapeutically and diagnostically. These methods are also useful as tools, for example, for

detecting and determining the role of Fas, FasL and Fap-1 in various cell functions and physiological processes and conditions and for diagnosing conditions associated with expression of Fas, FasL or Fap-1.

5           The present invention also comprises methods for diagnosing and treating autoimmune and inflammatory diseases, particularly hepatitis, and cancers, including those of the colon, liver and lung, and lymphomas. These methods are believed to be useful, for example, in  
10   diagnosing Fas, FasL and Fap-1-associated disease progression. These methods employ the antisense compounds of the invention. These methods are believed to be useful both therapeutically, including prophylactically, and as clinical research and diagnostic tools.

15           In accordance with the present invention, compositions for inhibiting allograft rejection, ischemia reperfusion injury and apoptosis are provided. These compositions comprise an antisense oligonucleotide which is targeted to a nucleic acid sequence encoding Fas.

20           Also in accordance with the present invention, methods of inhibiting allograft rejection, ischemia reperfusion injury and apoptosis are provided which comprise treating an allograft recipient with an antisense oligonucleotide which is targeted to a nucleic acid  
25   sequence encoding Fas. In addition, the allograft may be treated with the antisense oligonucleotide, ex vivo.

#### **DETAILED DESCRIPTION OF THE INVENTION**

Fas, FasL and Fap-1 play important roles in signal transduction. Overexpression and/or constitutive  
30   activation of Fas, FasL or Fap-1 is associated with a number of autoimmune and inflammatory diseases, and cancers. As such, these proteins involved in signal transduction represent attractive targets for treatment of

such diseases. In particular, modulation of the expression of Fas, FasL or Fap-1 may be useful for the treatment of diseases such as hepatitis, colon cancer, liver cancer, lung cancer and lymphomas.

5           The present invention employs antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding Fas, FasL and Fap-1, ultimately modulating the amount of Fas, FasL or Fap-1 produced. This is accomplished by providing  
10 oligonucleotides which specifically hybridize with nucleic acids, preferably mRNA, encoding Fas, FasL or Fap-1.

          This relationship between an antisense compound such as an oligonucleotide and its complementary nucleic acid target, to which it hybridizes, is commonly referred to as  
15 "antisense". "Targeting" an oligonucleotide to a chosen nucleic acid target, in the context of this invention, is a multistep process. The process usually begins with identifying a nucleic acid sequence whose function is to be modulated. This may be, as examples, a cellular gene (or  
20 mRNA made from the gene) whose expression is associated with a particular disease state, or a foreign nucleic acid from an infectious agent. In the present invention, the targets are nucleic acids encoding Fas, FasL or Fap-1; in other words, a gene encoding Fas, FasL or Fap-1, or mRNA  
25 expressed from the Fas, FasL or Fap-1 gene. mRNA which encodes Fas, FasL or Fap-1 is presently the preferred target. The targeting process also includes determination of a site or sites within the nucleic acid sequence for the antisense interaction to occur such that modulation of gene  
30 expression will result.

          In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA includes not only the information to encode a protein using the three letter genetic code, but also associated

ribonucleotides which form a region known to such persons as the 5'-untranslated region, the 3'-untranslated region, the 5' cap region and intron/exon junction ribonucleotides. Thus, oligonucleotides may be formulated in accordance with  
5 this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the informational ribonucleotides. The oligonucleotide may therefore be specifically hybridizable with a transcription initiation site region, a translation initiation codon  
10 region, a 5' cap region, an intron/exon junction, coding sequences, a translation termination codon region or sequences in the 5'- or 3'-untranslated region. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in  
15 the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon." A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have  
20 been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (prokaryotes). It is also  
25 known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start  
30 codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding Fas, FasL or Fap-1, regardless of the sequence(s) of such codons. It is also known in the art that a



translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region,"

5 "AUG region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. This region is a preferred target region.

10 Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. This region is a

15 preferred target region. The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other preferred target regions

20 include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on

25 the gene and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on

30 the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself

as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns", which are excised from a pre-mRNA transcript to yield one or more mature mRNA. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., exon-exon or intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. Targeting particular exons in alternatively spliced mRNAs may also be preferred. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once the target site or sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired modulation.

"Hybridization", in the context of this invention, means hydrogen bonding, also known as Watson-Crick base pairing, between complementary bases, usually on opposite nucleic acid strands or two regions of a nucleic acid strand. Guanine and cytosine are examples of complementary bases which are known to form three hydrogen bonds between them. Adenine and thymine are examples of complementary bases which form two hydrogen bonds between them.

"Specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity such that stable and specific binding occurs between the DNA or RNA target and the  
5 oligonucleotide.

It is understood that an oligonucleotide need not be 100% complementary to its target nucleic acid sequence to be specifically hybridizable. An oligonucleotide is specifically hybridizable when binding of the  
10 oligonucleotide to the target interferes with the normal function of the target molecule to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the oligonucleotide to non-target sequences under conditions in which specific binding  
15 is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment or, in the case of *in vitro* assays, under conditions in which the assays are conducted.

Hybridization of antisense oligonucleotides with mRNA  
20 interferes with one or more of the normal functions of mRNA. The functions of mRNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or  
25 more mRNA species, and catalytic activity which may be engaged in by the RNA. Binding of specific protein(s) to the RNA may also be interfered with by antisense oligonucleotide hybridization to the RNA.

The overall effect of interference with mRNA function  
30 is modulation of expression of Fas, FasL or Fap-1. In the context of this invention "modulation" means either inhibition or stimulation; i.e., either a decrease or increase in expression. This modulation can be measured in ways which are routine in the art, for example by Northern

blot assay of mRNA expression, or reverse transcriptase PCR, as taught in the examples of the instant application or by Western blot or ELISA assay of protein expression, or by an immunoprecipitation assay of protein expression.

- 5 Effects on cell proliferation or tumor cell growth can also be measured, as taught in the examples of the instant application. Inhibition is presently preferred.

The oligonucleotides of this invention can be used in diagnostics, therapeutics, prophylaxis, and as research  
10 reagents and in kits. Since the oligonucleotides of this invention hybridize to nucleic acids encoding Fas, FasL or Fap-1, sandwich, colorimetric and other assays can easily be constructed to exploit this fact. Provision of means for detecting hybridization of oligonucleotide with the  
15 Fas, FasL or Fap-1 genes or mRNA can routinely be accomplished. Such provision may include enzyme conjugation, radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of Fas, FasL or Fap-1 may also be prepared.

20 The present invention is also suitable for diagnosing abnormal inflammatory states or certain cancers in tissue or other samples from patients suspected of having an autoimmune or inflammatory disease such as hepatitis or cancers such as those of the colon, liver or lung, and  
25 lymphomas. A number of assays may be formulated employing the present invention, which assays will commonly comprise contacting a tissue sample with an oligonucleotide of the invention under conditions selected to permit detection and, usually, quantitation of such inhibition. In the  
30 context of this invention, to "contact" tissues or cells with an oligonucleotide or oligonucleotides means to add the oligonucleotide(s), usually in a liquid carrier, to a cell suspension or tissue sample, either *in vitro* or *ex*

vivo, or to administer the oligonucleotide(s) to cells or tissues within an animal.

The oligonucleotides of this invention may also be used for research purposes. Thus, the specific  
5 hybridization exhibited by the oligonucleotides may be used for assays, purifications, cellular product preparations and in other methodologies which may be appreciated by persons of ordinary skill in the art.

In the context of this invention, the term  
10 "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent intersugar (backbone) linkages as well as oligonucleotides having non-naturally-  
15 occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced binding to target and increased stability in the presence of  
20 nucleases.

The antisense compounds in accordance with this invention preferably comprise from about 5 to about 50 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30  
25 nucleobases (i.e. from about 8 to about 30 linked nucleosides). As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the  
30 pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2=, 3= or 5= hydroxyl moiety of the

sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to  
5 form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and  
10 DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this  
15 specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides  
20 that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters,  
25 aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates,  
30 thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to

5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent 3,687,808; 5 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 10 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or 15 cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone 20 backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S 25 and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 30 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent 5,539,082; 5,714,331; and 5,719,262. Further teaching of PNA compounds can be found in Nielsen et al. (*Science*, **1991**, 254, 1497-1500).

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular  $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$  [known as a methylene (methylimino) or MMI backbone],  $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$ ,  $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$  and  $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$  [wherein the native phosphodiester backbone is represented as  $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$ ] of the above referenced U.S. Patent 5,489,677, and the amide backbones of the above referenced U.S. Patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl, O-alkyl-O-alkyl, O-,



S-, or N-alkenyl, or O-, S- or N-alkynyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C<sub>1</sub> to C<sub>10</sub> alkyl or C<sub>2</sub> to C<sub>10</sub> alkenyl and alkynyl. Particularly preferred are O[(CH<sub>2</sub>)<sub>n</sub>O]<sub>m</sub>CH<sub>3</sub>,  
5 O(CH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>, O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>, O(CH<sub>2</sub>)<sub>n</sub>ONH<sub>2</sub>, and O(CH<sub>2</sub>)<sub>n</sub>ON[(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub>]<sub>2</sub>, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C<sub>1</sub> to C<sub>10</sub> lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH<sub>3</sub>, OCN, Cl, Br, CN, CF<sub>3</sub>, OCF<sub>3</sub>, SOCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>,  
10 ONO<sub>2</sub>, NO<sub>2</sub>, N<sub>3</sub>, NH<sub>2</sub>, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an  
15 oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al.,  
20 *Helv. Chim. Acta* **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a O(CH<sub>2</sub>)<sub>2</sub>ON(CH<sub>3</sub>)<sub>2</sub> group, also known as 2'-DMAOE, and 2'-dimethylamino-ethoxyethoxy (2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>.  
25 Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in  
30 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugars

structures include, but are not limited to, U.S. Patent  
4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878;  
5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811;  
5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,0531  
5 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920.

Oligonucleotides may also include nucleobase (often  
referred to in the art simply as "base") modifications or  
substitutions. As used herein, "unmodified" or "natural"  
nucleobases include the purine bases adenine (A) and  
10 guanine (G), and the pyrimidine bases thymine (T), cytosine  
(C) and uracil (U). Modified nucleobases include other  
synthetic and natural nucleobases such as 5-methylcytosine  
(5-me-C or m5c), 5-hydroxymethyl cytosine, xanthine,  
hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl  
15 derivatives of adenine and guanine, 2-propyl and other  
alkyl derivatives of adenine and guanine, 2-thiouracil, 2-  
thiothymine and 2-thiocytosine, 5-halouracil and cytosine,  
5-propynyl uracil and cytosine, 6-azo uracil, cytosine and  
thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-  
20 amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-  
substituted adenines and guanines, 5-halo particularly 5-  
bromo, 5-trifluoromethyl and other 5-substituted uracils  
and cytosines, 7-methylguanine and 7-methyladenine, 8-  
azaguanine and 8-azaadenine, 7-deazaguanine and 7-  
25 deazaadenine and 3-deazaguanine and 3-deazaadenine.

Further nucleobases include those disclosed in United  
States Patent 3,687,808, those disclosed in the *Concise  
Encyclopedia Of Polymer Science And Engineering* **1990**, pages  
858-859, Kroschwitz, J.I., ed. John Wiley & Sons, those  
30 disclosed by Englisch et al. (*Angewandte Chemie,  
International Edition* **1991**, 30, 613-722), and those  
disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research  
and Applications* **1993**, pages 289-302, Crooke, S.T. and  
Lebleu, B., ed., CRC Press. Certain of these nucleobases

are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications* **1993**, CRC Press, Boca Raton, pages 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Patent 3,687,808, as well as U.S. Patent 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA **1989**, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett. **1994**, 4, 1053-1059), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci. **1992**, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett. **1993**, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res. **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et

al., EMBO J. **1991**, 10, 1111-1118; Kabanov et al., FEBS Lett. **1990**, 259, 327-330; Svinarchuk et al., Biochimie **1993**, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett. **1995**, 36, 3651-3654; Shea et al., Nucl. Acids Res. **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett. **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther. **1996**, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Patent 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928; and 5,688,941.

The present invention also includes oligonucleotides which are chimeric oligonucleotides. "Chimeric" oligonucleotides or "chimeras," in the context of this invention, are oligonucleotides which contain two or more

chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance  
5 to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular  
10 endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense inhibition of gene expression. Cleavage of the RNA target can be routinely detected by gel  
15 electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. This RNase H-mediated cleavage of the RNA target is distinct from the use of ribozymes to cleave nucleic acids. Ribozymes are not comprehended by the present invention.

20 Examples of chimeric oligonucleotides include but are not limited to "gapmers," in which three distinct regions are present, normally with a central region flanked by two regions which are chemically equivalent to each other but distinct from the gap. A preferred example of a gapmer is  
25 an oligonucleotide in which a central portion (the "gap") of the oligonucleotide serves as a substrate for RNase H and is preferably composed of 2'-deoxynucleotides, while the flanking portions (the 5' and 3' "wings") are modified to have greater affinity for the target RNA molecule but  
30 are unable to support nuclease activity (e.g., fluoro- or 2'-O-methoxyethyl- substituted). Chimeric oligonucleotides are not limited to those with modifications on the sugar, but may also include oligonucleosides or oligonucleotides with modified backbones, e.g., with regions of

phosphorothioate (P=S) and phosphodiester (P=O) backbone linkages or with regions of MMI and P=S backbone linkages. Other chimeras include "wingmers," also known in the art as "hemimers," that is, oligonucleotides with two distinct  
5 regions. In a preferred example of a wingmer, the 5' portion of the oligonucleotide serves as a substrate for RNase H and is preferably composed of 2'-deoxynucleotides, whereas the 3' portion is modified in such a fashion so as to have greater affinity for the target RNA molecule but is  
10 unable to support nuclease activity (e.g., 2'-fluoro- or 2'-O-methoxyethyl- substituted), or vice-versa. In one embodiment, the oligonucleotides of the present invention contain a 2'-O-methoxyethyl (2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>) modification on the sugar moiety of at least one nucleotide. This  
15 modification has been shown to increase both affinity of the oligonucleotide for its target and nuclease resistance of the oligonucleotide. According to the invention, one, a plurality, or all of the nucleotide subunits of the oligonucleotides of the invention may bear a 2'-O-  
20 methoxyethyl (-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>) modification. Oligonucleotides comprising a plurality of nucleotide subunits having a 2'-O-methoxyethyl modification can have such a modification on any of the nucleotide subunits within the oligonucleotide, and may be chimeric oligonucleotides. Aside from or in  
25 addition to 2'-O-methoxyethyl modifications, oligonucleotides containing other modifications which enhance antisense efficacy, potency or target affinity are also preferred. Chimeric oligonucleotides comprising one or more such modifications are presently preferred.

30 The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such

synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of the routineer. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and 2'-alkoxy or 2'-alkoxyalkoxy derivatives, including 2'-O-methoxyethyl oligonucleotides (Martin, P., *Helv. Chim. Acta* **1995**, 78, 486-504). It is also well known to use similar techniques and commercially available modified amidites and controlled-pore glass (CPG) products such as biotin, fluorescein, acridine or psoralen-modified amidites and/or CPG (available from Glen Research, Sterling, VA) to synthesize fluorescently labeled, biotinylated or other conjugated oligonucleotides.

The antisense compounds of the present invention include bioequivalent compounds, including pharmaceutically acceptable salts and prodrugs. This is intended to encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of the nucleic acids of the invention and prodrugs of such nucleic acids. Pharmaceutically acceptable salts are physiologically and pharmaceutically acceptable salts of the nucleic acids of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.* **1977**, 66, 1-19).

For oligonucleotides, examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium,

magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

15           The oligonucleotides of the invention may additionally or alternatively be prepared to be delivered in a Aprodug® form. The term Aprodug® indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 25 93/24510 to Gosselin et al., published December 9, 1993.

For therapeutic or prophylactic treatment, oligonucleotides are administered in accordance with this invention. Oligonucleotide compounds of the invention may be formulated in a pharmaceutical composition, which may include pharmaceutically acceptable carriers, thickeners, 30 diluents, buffers, preservatives, surface active agents, neutral or cationic lipids, lipid complexes, liposomes, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients and the



like in addition to the oligonucleotide. Such compositions and formulations are comprehended by the present invention.

Pharmaceutical compositions comprising the oligonucleotides of the present invention may include

5 penetration enhancers in order to enhance the alimentary delivery of the oligonucleotides. Penetration enhancers may be classified as belonging to one of five broad categories, i.e., fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et al., *Critical*

10 *Reviews in Therapeutic Drug Carrier Systems* **1991**, *8*, 91-192; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems* **1990**, *7*, 1-33). One or more penetration enhancers from one or more of these broad categories may be included.

15 Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (a.k.a. 1-monooleoyl-*rac*-

20 glycerol), dilaurin, caprylic acid, arachidonic acid, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono- and di-glycerides and physiologically acceptable salts thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate,

25 linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems* **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems* **1990**, *7*, 1; El-Hariri et al., *J. Pharm. Pharmacol.* **1992** *44*, 651-654).

30 The physiological roles of bile include the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 *In: Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, **1996**,

pages 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus, the term "bile salt" includes any of the naturally occurring components of bile as well as any of their  
5 synthetic derivatives.

Complex formulations comprising one or more penetration enhancers may be used. For example, bile salts may be used in combination with fatty acids to make complex formulations.

10 Chelating agents include, but are not limited to, disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), *N*-acyl derivatives of collagen, laureth-9 and *N*-amino acyl derivatives of beta-diketones  
15 (enamines)[Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems* **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems* **1990**, 7, 1-33; Buur et al., *J. Control Rel.* **1990**, 14, 43-51). Chelating agents have the added advantage of also serving as DNase  
20 inhibitors.

Surfactants include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems* **1991**, page 92);  
25 and perfluorochemical emulsions, such as FC-43 (Takahashi et al., *J. Pharm. Pharmacol.* **1988**, 40, 252-257).

Non-surfactants include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems* **1991**, page 92); and non-steroidal  
30 anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.* **1987**, 39, 621-626).

As used herein, "carrier compound" refers to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the  
5 bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance,  
10 can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. In contrast to a carrier compound, a  
15 "pharmaceutically acceptable carrier" (excipient) is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The pharmaceutically acceptable carrier may be liquid or solid  
20 and is selected with the planned manner of administration in mind so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutically acceptable carriers include, but are not  
25 limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium  
30 hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrates (e.g., starch, sodium starch

glycolate, etc.); or wetting agents (e.g., sodium lauryl sulphate, etc.). Sustained release oral delivery systems and/or enteric coatings for orally administered dosage forms are described in U.S. Patents 4,704,295; 4,556,552; 5 4,309,406; and 4,309,404.

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the 10 compositions may contain additional compatible pharmaceutically-active materials such as, e.g., antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage 15 forms of the composition of present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the 20 compositions of the invention.

Regardless of the method by which the oligonucleotides of the invention are introduced into a patient, colloidal dispersion systems may be used as delivery vehicles to enhance the *in vivo* stability of the 25 oligonucleotides and/or to target the oligonucleotides to a particular organ, tissue or cell type. Colloidal dispersion systems include, but are not limited to, macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions, 30 micelles, mixed micelles, liposomes and lipid:oligonucleotide complexes of uncharacterized structure. A preferred colloidal dispersion system is a plurality of liposomes. Liposomes are microscopic spheres having an aqueous core surrounded by one or more outer

layers made up of lipids arranged in a bilayer configuration (see, generally, Chonn et al., *Current Op. Biotech.* **1995**, 6, 698-708).

The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, epidermal, and transdermal), oral or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, pulmonary administration, e.g., by inhalation or insufflation, or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. In some cases it may be more effective to treat a patient with an oligonucleotide of the invention in conjunction with other traditional therapeutic modalities in order to increase the

efficacy of a treatment regimen. In the context of the invention, the term "treatment regimen" is meant to encompass therapeutic, palliative and prophylactic modalities. For example, a patient may be treated with  
5 conventional chemotherapeutic agents, particularly those used for tumor and cancer treatment. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide,  
10 ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone,  
15 amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptapurine, 6-thioguanine, cytarabine (CA), 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramidate, 5-fluorouracil (5-FU), 5-  
20 fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide, trimetrexate, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. **1987**, pp. 1206-1228, Berkow et al., eds.,  
25 Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination  
30 with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide).

For prophylactics and therapeutics, methods of preventing, inhibiting and treating allograft rejection are

provided. The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill in the art. While administration of therapeutics to the allograft recipient via varying routes prior to  
5 transplantation can serve to inhibit or prevent allograft rejection, prevention of allograft rejection *ex vivo* (perfusion of the allograft prior to transplantation) may be preferred. Methods of organ perfusion are well known in the art. In general, harvested tissues or organs  
10 (preferably heart or kidney) are perfused with the compositions of the invention in a pharmacologically acceptable carrier such as, for example, lactated Ringer's solution, University of Wisconsin (UW) solution, Euro-Collins solution or Sachs solution. Simple flushing of the  
15 organ or pulsatile perfusion may be used. Perfusion time is generally dependent on the length of *ex vivo* viability of the organ being transplanted; these viability times vary from organ to organ and are known in the art. Hearts and livers, for example, are generally transplanted within 4 to  
20 6 hours of harvesting, whereas other organs may have longer ischemic viability. Kidneys, for example, may be transplanted up to 48 hours or even 72 hours after harvesting. Dosage may range from 0.001 $\mu$ g to 500 g of oligonucleotide.

25 Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be  
30 calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and

can generally be estimated based on  $EC_{50}$ s found to be effective *in vitro* and in *in vivo* animal models. In general, dosage is from 0.01  $\mu$ g to 100 g per kg of body weight, and may be given once or more daily, weekly, 5 monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be 10 desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01  $\mu$ g to 100 g per kg of body weight, once or more daily, to once every 20 years.

15       The following examples illustrate the present invention and are not intended to limit the same.

## EXAMPLES

### EXAMPLE 1

#### Synthesis of Oligonucleotides

20       Unmodified oligodeoxynucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.  $\beta$ -cyanoethyl-diisopropyl-phosphoramidites are purchased from Applied Biosystems 25 (Foster City, CA). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of  $^3H$ -1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation cycle wait step was increased to 68 30 seconds and was followed by the capping step. Cytosines may be 5-methyl cytosines. (5-methyl deoxycytidine phosphoramidites available from Glen Research, Sterling, VA, or Amersham Pharmacia Biotech, Piscataway, NJ)



2'-methoxy oligonucleotides are synthesized using 2'-methoxy  $\beta$ -cyanoethyldiisopropyl-phosphoramidites (Chemgenes, Needham, MA) and the standard cycle for unmodified oligonucleotides, except the wait step after  
5 pulse delivery of tetrazole and base is increased to 360 seconds. Other 2'-alkoxy oligonucleotides are synthesized by a modification of this method, using appropriate 2'-modified amidites such as those available from Glen Research, Inc., Sterling, VA.

10 2'-fluoro oligonucleotides are synthesized as described in Kawasaki et al. (*J. Med. Chem.* **1993**, 36, 831-841). Briefly, the protected nucleoside N<sup>6</sup>-benzoyl-2'-deoxy-2'-fluoroadenosine is synthesized utilizing commercially available 9- $\beta$ -D-arabinofuranosyladenine as  
15 starting material and by modifying literature procedures whereby the 2'-a-fluoro atom is introduced by a S<sub>N</sub>2-displacement of a 2'- $\beta$ -O-triflyl group. Thus N<sup>6</sup>-benzoyl-9- $\beta$ -D-arabinofuranosyladenine is selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP)  
20 intermediate. Deprotection of the THP and N<sup>6</sup>-benzoyl groups is accomplished using standard methodologies and standard methods are used to obtain the 5'-dimethoxytrityl- (DMT) and 5'-DMT-3'-phosphoramidite intermediates.

The synthesis of 2'-deoxy-2'-fluoroguanosine is  
25 accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9- $\beta$ -D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group is followed by protection of the hydroxyl group with THP to  
30 give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation is followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies are used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

Synthesis of 2'-deoxy-2'-fluorouridine is accomplished by the modification of a known procedure in which 2, 2'-anhydro-1- $\beta$ -D-arabinofuranosyluracil is treated with 70% hydrogen fluoride-pyridine. Standard procedures  
5 are used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-deoxy-2'-fluorocytidine is synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N<sup>4</sup>-benzoyl-2'-deoxy-2'-  
10 fluorocytidine. Standard procedures are used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-(2-methoxyethyl)-modified amidites were synthesized according to Martin, P. (*Helv. Chim. Acta* **1995**, 78, 486-506). For ease of synthesis, the last nucleotide  
15 may be a deoxynucleotide. 2'-O-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>-cytosines may be 5-methyl cytosines.

*Synthesis of 5-Methyl cytosine monomers:*

**2,2'-Anhydro[1-( $\beta$ -D-arabinofuranosyl)-5-methyluridine]:**

5-Methyluridine (ribosylthymine, commercially  
20 available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner.  
25 After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca.  
30 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 hours) to

give a solid which was crushed to a light tan powder (57 g, 85% crude yield). The material was used as is for further reactions.

**2'-O-Methoxyethyl-5-methyluridine:**

5           2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened  
10 and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica  
15 gel column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3) containing 0.5% Et<sub>3</sub>NH. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product.

20 **2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine:**

          2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and  
25 the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70%  
30 product. The solvent was evaporated and triturated with CH<sub>3</sub>CN (200 mL). The residue was dissolved in CHCl<sub>3</sub> (1.5 L) and extracted with 2x500 mL of saturated NaHCO<sub>3</sub> and 2x500 mL

of saturated NaCl. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/Hexane/Acetone (5:5:1) containing 0.5% Et<sub>3</sub>NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine:**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by tlc by first quenching the tlc sample with the addition of MeOH. Upon completion of the reaction, as judged by tlc, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl<sub>3</sub> (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl<sub>3</sub>. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/Hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%).

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine:**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH<sub>3</sub>CN (700 mL) and set

aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH<sub>3</sub>CN (1 L), cooled to -5°C and stirred for 0.5 hour using an overhead stirrer. POCl<sub>3</sub> was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the later solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO<sub>3</sub> and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine:**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH<sub>4</sub>OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH<sub>3</sub> gas was added and the vessel heated to 100°C for 2 hours (tlc showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N<sup>4</sup>-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine:**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and  
5 benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, tlc showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl<sub>3</sub> (700 mL) and extracted  
10 with saturated NaHCO<sub>3</sub> (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO<sub>4</sub> and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/Hexane (1:1) containing 0.5% Et<sub>3</sub>NH as the eluting solvent. The pure product fractions were  
15 evaporated to give 90 g (90%) of the title compound.

**N<sup>4</sup>-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite:**

N<sup>4</sup>-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1  
20 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxytetra(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (tlc showed the reaction to be 95% complete). The reaction  
25 mixture was extracted with saturated NaHCO<sub>3</sub> (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH<sub>2</sub>Cl<sub>2</sub> (300 mL), and the extracts were combined, dried over MgSO<sub>4</sub> and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column  
30 using EtOAc\Hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.

5-methyl-2'-deoxycytidine (5-me-C) containing oligonucleotides were synthesized according to published methods (Sanghvi et al., *Nucl. Acids Res.* **1993**, 21, 3197-3203) using commercially available phosphoramidites (Glen Research, Sterling, VA, or ChemGenes, Needham, MA).

**2'-O-(dimethylaminooxyethyl) nucleoside amidites:**

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

**5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine:**

O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0 g, 0.416 mmol), dimethylaminopyridine (0.66 g, 0.013 eq, 0.0054 mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. *tert*-Butyldiphenylchlorosilane (125.8 g, 119.0 mL, 1.1 eq, 0.458 mmol) was added in one portion. The reaction was stirred for 16 hours at ambient temperature. TLC (R<sub>f</sub> 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600 mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl

ether (3x200 mL) and dried (40°C, 1 mm Hg, 24 hours) to 149 g (74.8%) of white solid. TLC and NMR were consistent with pure product.

**5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-**

**5 methyluridine:**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until  
10 the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160°C  
15 was reached and then maintained for 16 hours (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (R<sub>f</sub> 0.67 for desired product and R<sub>f</sub> 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional  
20 side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1 mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can  
25 be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2 kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a  
30 white crisp foam (84 g, 50%), contaminated starting material (17.4 g) and pure reusable starting material 20 g. The yield based on starting material less pure recovered



starting material was 58%. TLC and NMR were consistent with 99% pure product.

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine:**

5           5'-O-tert-Butylldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20 g, 36.98 mol.) was mixed with triphenylphosphine (11.63 g, 44.36 mol.) and N-hydroxyphthalimide (7.24 g, 44.36 mol.). It was then dried over P<sub>2</sub>O<sub>5</sub> under high vacuum for two days at 40°C. The  
10 reaction mixture was flushed with argon and dry THF (369.8 mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98 mL, 44.36 mol.) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red  
15 coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hours. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a  
20 flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine as white foam (21.819, 86%).

**5'-O-tert-butylldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine:**

25           2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine (3.1 g, 4.5 mol.) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (4.5 mL) and methylhydrazine (300 mL, 4.64 mol.) was added dropwise at -10°C to 0°C. After 1  
30 hour the mixture was filtered, the filtrate was washed with ice cold CH<sub>2</sub>Cl<sub>2</sub> and the combined organic phase was washed with water, brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The

solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5 mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eg.) was added and the mixture for 1 hour. Solvent was removed  
5 under vacuum; residue chromatographed to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95, 78%).

**5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine:**

10        5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77 g, 3.12 mol.) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6 mL). Sodium cyanoborohydride (0.39 g, 6.13 mol.) was added to this  
15 solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 hours, the reaction monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Aqueous NaHCO<sub>3</sub> solution (5%, 10 mL)  
20 was added and extracted with ethyl acetate (2x20 mL). Ethyl acetate phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6 mL). Formaldehyde (20% w/w, 30 mL, 3.37 mol.) was added and the reaction mixture was  
25 stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39 g, 6.13 mol.) was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and  
30 stirred at room temperature for 2 hours. To the reaction mixture 5% NaHCO<sub>3</sub> (25 mL) solution was added and extracted with ethyl acetate (2x25 mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness . The

residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam (14.6 g, 80%).

5 **2'-O-(dimethylaminoxyethyl)-5-methyluridine:**

Triethylamine trihydrofluoride (3.91 mL, 24.0 mol.) was dissolved in dry THF and triethylamine (1.67 mL, 12 mol., dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-  
10 [N,N-dimethylaminoxyethyl]-5-methyluridine (1.40 g, 2.4 mol.) and stirred at room temperature for 24 hours. Reaction was monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 2'-O-  
15 (dimethylaminoxyethyl)-5-methyluridine (766 mg, 92.5%).

**5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine:**

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750 mg, 2.17 mol.) was dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. It was then co-evaporated with anhydrous pyridine  
20 (20 mL). The residue obtained was dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mol.), 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mol.) was added to the mixture and the reaction mixture was stirred at room temperature until all of the  
25 starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13 g, 80%).

**5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]:**

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine  
5 (1.08 g, 1.67 mol.) was co-evaporated with toluene (20 mL). To the residue N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mol.) was added and dried over P<sub>2</sub>O<sub>5</sub> under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-  
10 N,N,N<sup>1</sup>,N<sup>1</sup>-tetraisopropylphosphoramidite (2.12 mL, 6.08 mol.) was added. The reaction mixture was stirred at ambient temperature for 4 hours under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue  
15 was dissolved in ethyl acetate (70 mL) and washed with 5% aqueous NaHCO<sub>3</sub> (40 mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-  
20 cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04 g, 74.9%).

Oligonucleotides having methylene (methylimino) (MMI) backbones are synthesized according to U.S. Patent 5,378,825, which is coassigned to the assignee of the  
25 present invention and is incorporated herein in its entirety. For ease of synthesis, various nucleoside dimers containing MMI linkages are synthesized and incorporated into oligonucleotides. Other nitrogen-containing backbones are synthesized according to WO 92/20823 which is also  
30 coassigned to the assignee of the present invention and incorporated herein in its entirety.

Oligonucleotides having amide backbones are synthesized according to De Mesmaeker et al. (*Acc. Chem. Res.* **1995**, 28, 366-374). The amide moiety is readily

accessible by simple and well-known synthetic methods and is compatible with the conditions required for solid phase synthesis of oligonucleotides.

Oligonucleotides with morpholino backbones are synthesized according to U.S. Patent 5,034,506 (Summerton and Weller).

Peptide-nucleic acid (PNA) oligomers are synthesized according to P.E. Nielsen et al. (*Science* **1991**, 254, 1497-1500).

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels or capillary gel electrophoresis and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by <sup>31</sup>P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al. (*J. Biol. Chem.* **1991**, 266, 18162). Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

## EXAMPLE 2

### Human Fas Oligonucleotide Sequences

Antisense oligonucleotides were designed to target human Fas. Target sequence data are from the APO-1 cDNA sequence published by Oehm, A., et al. (*J. Biol. Chem.*, **1992**, 267, 10709-10715); Genbank accession number X63717, provided herein as SEQ ID NO: 1. Oligonucleotides were synthesized as chimeric oligonucleotides ("gapmers")

nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings." The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All 2'-MOE cytosines were 5-methylcytosines. These oligonucleotide sequences are shown in Table 1.

10       The C8161 melanoma cell line was obtained from Welch D.R., et al. (*Int. J. Cancer*, **1991**, 47, 227-237). C8161 cells were cultured in RPMI 1640 medium plus 10% fetal bovine serum (Hyclone, Logan, UT).

          C8161 cells ( $5.5 \times 10^5$  cells) were plated onto 100 cm  
15 plates. Two days later, the cells were washed once with OPTIMEM™ (Life Technologies, Rockville, MD), then transfected with 300 nM oligonucleotide and 15 g/ml LIPOFECTIN<sup>7</sup> (Life Technologies, Rockville, MD), a 1:1 (w/w) liposome formulation of the cationic lipid N-[1-(2,3-  
20 dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA), and dioleoyl phosphotidylethanolamine (DOPE) in membrane filtered water. The cells were incubated with oligonucleotide for four hours, after which the media was replaced with fresh media and the cells incubated for  
25 another 20 hours.

          Total cellular RNA was isolated using the RNEASY<sup>7</sup> kit (Qiagen, Santa Clarita, CA). RNA was then separated on a 1% agarose gel, transferred to Hybond-N+ membrane (Amersham, Arlington Heights, IL), a positively charged  
30 nylon membrane, and probed. A Fas probe was generated by random primer labeling of a RT-PCR amplified fragment of Fas mRNA.

          A glyceraldehyde 3-phosphate dehydrogenase (G3PDH) probe was purchased from Clontech (Palo Alto, CA), Catalog

Number 9805-1. The probes were labeled by random primer using the Large Fragment of DNA polymerase (Klenow fragment) (GIBCO BRL) as described in Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, **1989**. mRNA was  
 5 quantitated by a PhosphoImager (Molecular Dynamics, Sunnyvale, CA).

Results of an initial screen of Fas antisense oligonucleotides is shown in Table 2. Oligonucleotides 17014 (SEQ ID NO. 5), 17015 (SEQ ID NO. 6), 17016 (SEQ ID  
 10 NO. 7), 17017 (SEQ ID NO. 8), 17019 (SEQ ID NO. 10), 17020 (SEQ ID NO. 11), 17021 (SEQ ID NO. 12), 17022 (SEQ ID NO. 13), 17023 (SEQ ID NO. 14), 17024 (SEQ ID NO. 15), 17025 (SEQ ID NO. 16), 17026 (SEQ ID NO. 17), 17028 (SEQ ID NO. 19), 17029 (SEQ ID NO. 20), and 17030 (SEQ ID NO. 21)  
 15 resulted in at least 60% inhibition of Fas mRNA expression in this assay. Oligonucleotides 17016 (SEQ ID NO. 7), 17017 (SEQ ID NO. 8), 17019 (SEQ ID NO. 10), 17020 (SEQ ID NO. 11), 17021 (SEQ ID NO. 12), 17022 (SEQ ID NO. 13), 17023 (SEQ ID NO. 14), 17024 (SEQ ID NO. 15), 17025 (SEQ ID  
 20 NO. 16), and 17026 (SEQ ID NO. 17) resulted in at least 80% inhibition of Fas mRNA expression.

TABLE 1

**Nucleotide Sequences of Human Fas Chimeric (deoxy gapped)  
 Phosphorothioate Oligonucleotides**

25	ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
	17012	CGTAAACCGCTTCCCTCACT	3	0040-0059	5'-UTR
	17013	GTGTTCCGTGCCAGTGCCCG	4	0085-0104	5'-UTR
	17014	GCCCAGCATGGTTGTTGAGC	5	0210-0229	AUG
30	17015	CTTCCTCAATTCCAATCCCT	6	0318-0337	coding

5	17016	<b>CTTCTTGGCAGGGCACGCAG</b>	7	0463-0482	coding
	17017	<b>TGCACTTGGTATTCTGGGTC</b>	8	0583-0602	coding
	17018	<b>GCTGGTGAGTGTGCATTTCCT</b>	9	0684-0703	coding
	17019	<b>CATTGACACCATTCTTTTCA</b>	10	0967-0986	coding
	17020	<b>TCACTCTAGACCAAGCTTTG</b>	11	1214-1233	stop
10	17021	<b>CCCAGTAAAAACCAAGCAG</b>	12	1305-1324	3'-UTR
	17022	<b>TATGTTGGCTCTTCAGCGCT</b>	13	1343-1362	3'-UTR
	17023	<b>ATTTGGGTACTTAGCATGCC</b>	14	1452-1471	3'-UTR
	17024	<b>GGGTTAGCCTGTGGATAGAC</b>	15	1568-1587	3'-UTR
	17025	<b>CAAAGTGGCCTGCCTGTTCA</b>	16	1641-1660	3'-UTR
15	17026	<b>TTGAGCCAGTAAAATGCATA</b>	17	1890-1909	3'-UTR
	17027	<b>TGAGCACCAAGGCAAAATG</b>	18	1983-2002	3'-UTR
	17028	<b>TCTTGCCTTTTGGTGGACTA</b>	19	2057-2076	3'-UTR
	17029	<b>AGCAGGTTTTACATGGGACA</b>	20	2222-2241	3'-UTR
	17030	<b>GGTATGACAAGAGCAATTCC</b>	21	2291-2310	3'-UTR
	17031	<b>GGTGGTTCCAGGTATCTGCT</b>	22	2450-2469	3'-UTR
	17032	<b>TATAATTCCAAACACAAGGG</b>	23	2503-2522	3'-UTR

<sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues, 2'-methoxyethoxy cytosine residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

<sup>2</sup> Coordinates from Genbank Accession No. X63717, locus name "HSAPO1", SEQ ID NO. 1.

TABLE 2

Inhibition of Human Fas mRNA expression in C8161 Cells by Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides

ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
control	---	---	100.0%	0.0%
17012	3	5'-UTR	98.7%	1.3%



ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
17013	4	5'-UTR	81.3%	18.7%
17014	5	AUG	27.1%	72.9%
17015	6	coding	30.0%	70.0%
17016	7	coding	8.7%	91.3%
5 17017	8	coding	10.1%	89.9%
17018	9	coding	186.1%	---
17019	10	coding	12.9%	87.1%
17020	11	stop	7.3%	92.7%
17021	12	3'-UTR	15.8%	84.2%
10 17022	13	3'-UTR	15.1%	84.9%
17023	14	3'-UTR	11.4%	88.6%
17024	15	3'-UTR	11.3%	88.7%
17025	16	3'-UTR	9.4%	90.6%
17026	17	3'-UTR	19.6%	80.4%
15 17027	18	3'-UTR	54.3%	45.7%
17028	19	3'-UTR	26.6%	73.4%
17029	20	3'-UTR	23.6%	76.4%
17030	21	3'-UTR	35.5%	64.5%
17031	22	3'-UTR	75.1%	24.9%
20 17032	23	3'-UTR	58.4%	41.6%

The most active oligonucleotide, 17020 (SEQ ID NO. 11) was used in a dose response experiment. C8161 cells were grown and treated as described above except the concentration was varied as shown in Table 3. The

25 LIPOFECTIN<sup>7</sup> to oligonucleotide ratio was maintained at 3 µg/ml LIPOFECTIN<sup>7</sup> per 100 nM oligonucleotide. RNA was isolated and quantitated as described above. Included in this experiment were control oligonucleotides with 2, 4, or

6 base mismatches or a scrambled control oligonucleotide. These controls were tested at 300nM.

Results are shown in Table 3.

**TABLE 3**

5                   **Dose Response of C8161 cells to ISIS 17020**

ISIS #	SEQ ID	ASO Gene	Dose	% RNA	% RNA
	NO:	Target		Expression	Inhibition
control	---	---	---	100%	---
17020	11	stop	25 nM	50.6%	49.4%
"	"	"	50 nM	44.9%	55.1%
10	"	"	100 nM	28.1%	71.9%
"	"	"	150 nM	21.8%	78.2%
"	"	"	200 nM	24.2%	75.8%
"	"	"	300 nM	19.3%	80.7%
"	"	"	400 nM	20.6%	79.4%

15           From the dose response curve, oligonucleotide 17020 has an IC<sub>50</sub> of about 25 nM. Control oligonucleotides with 2, 4, or 6 base mismatches or a scrambled control oligonucleotide showed no inhibition of Fas mRNA expression.

20   **EXAMPLE 3**

**Human FasL Oligonucleotide Sequences**

Antisense oligonucleotides were designed to target human FasL. Target sequence data are from the Fas ligand cDNA sequence published by Mita, E. et al. (*Biochem.*  
25 *Biophys. Res. Commun.*, **1994**, 204, 468-474); Genbank accession number D38122, provided herein as SEQ ID NO: 24. Oligonucleotides were synthesized as chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten

2'deoxy nucleotides, which is flanked on both sides (5' and 3' directions) by five nucleotide "wings." The wings are composed of 2'methoxyethyl (2'MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All 2'-MOE cytosines were 5-methyl-cytosines. These oligonucleotide sequences are shown in Table 4.

NHEK cells, a human epidermal keratinocyte cell line was obtained from Clonetics (Walkersville, MD). NHEK were grown in Keratinocyte Growth Media (KGM) (Gibco BRL, Gaithersburg, MD) containing 5 NG/ml of EG., bovine pituitary extract. NHEK cells were used at passage 6.

NHEK were grown to 60-80% confluency, washed once with basal media, and then incubated for 4 hours with 5 ml of basal media containing 10 µg/ml LIPOFECTIN<sup>7</sup> (Gibco BRL, Gaithersburg, MD) and 300 nM of oligonucleotide. The media was replaced with fresh media and cells were incubated for an additional 20 hours.

Total cellular RNA was isolated by guanidinium isothiocyanate extraction followed by ultracentrifugation (see Ausubel, F.M. et al., Current Protocols in Molecular Biology, **1993**, John Wiley & Sons, Inc.). Northern blotting was performed as described in Example 2. A FasL probe was generated by PCR using FasL primers (Life Technologies). Signals from Northern blots were quantitated as described in Example 2.

Results are shown in Table 5. Oligonucleotides 16171 (SEQ ID NO. 36), 16172 (SEQ ID NO. 37), 16178 (SEQ ID NO. 43) and 16179 (SEQ ID NO. 44) resulted in at least 45% inhibition of Fas ligand mRNA expression in this assay.

TABLE 4

**Nucleotide Sequences of Human FasL Chimeric (deoxy gapped)  
Phosphorothioate Oligonucleotides**

5	ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
	16161	<b>CCATAGCTAAGGGAAACACC</b>	26	0034-0053	5'-UTR
	16162	<b>GCCAGCCCCAGCAAACGGTT</b>	27	0152-0171	5'-UTR
	16163	<b>TGCATGGCAGCTGGTGAGTC</b>	28	0174-0193	AUG
	16164	<b>GGAAGAACTGTGCCTGGAGG</b>	29	0261-0280	coding
10	16165	<b>TGGCAGCGGTAGTGGAGGCA</b>	30	0376-0395	coding
	16166	<b>GCTGTGTGCATCTGGCTGGT</b>	31	0540-0559	coding
	16167	<b>AATGGGCCACTTTCCTCAGC</b>	32	0614-0633	coding
	16168	<b>GCAGGTTGTTGCAAGATTGA</b>	33	0785-0804	coding
	16169	<b>AAGATTGAACACTGCCCCCA</b>	34	0922-0941	coding
15	16170	<b>AATCCCAAAGTGCTTCTCTT</b>	35	1033-1052	stop
	16171	<b>TTCTCGGTGCCTGTAACAAA</b>	36	1069-1088	3'-UTR
	16172	<b>GCTACAGACATTTTGAACCC</b>	37	1169-1188	3'-UTR
	16173	<b>CCGTCATATTCCTCCATTG</b>	38	1220-1239	3'-UTR
	16174	<b>CCCTCTTCACATGGCAGCCC</b>	39	1256-1275	3'-UTR
20	16175	<b>GGTGTCTTTTCAATCTGCC</b>	40	1338-1357	3'-UTR
	16176	<b>CAGTCCCCCTTGAGGTAGCA</b>	41	1385-1404	3'-UTR
	16177	<b>GTGAAGATGCTGCCAGTGGG</b>	42	1503-1522	3'-UTR
	16178	<b>CCCCTACAATTGGCACTGGA</b>	43	1618-1637	3'-UTR
	16179	<b>TCTTGACCAAATGCAACCCA</b>	44	1714-1733	3'-UTR

25 <sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues, 2'-methoxyethoxy cytosine residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

<sup>2</sup> Coordinates from Genbank Accession No. D31822, locus name "HUMHPC", SEQ ID NO. 24.

TABLE 5

Inhibition of Human FasL mRNA expression in NHEK Cells by  
Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides

5	ISIS	SEQ	GENE	% mRNA	% mRNA
	No:	ID	TARGET	EXPRESSION	INHIBITION
		NO:	REGION		
	control	---	---	100.0%	0.0%
	16161	26	5'-UTR	127.0%	---
	16162	27	5'-UTR	136.0%	---
	16163	28	AUG	119.0%	---
10	16164	29	coding	110.0%	---
	16165	30	coding	124.0%	---
	16166	31	coding	131.0%	---
	16167	32	coding	142.0%	---
	16168	33	coding	137.0%	---
15	16169	34	coding	111.0%	---
	16170	35	stop	108.0%	---
	16171	36	3'-UTR	53.0%	47.0%
	16172	37	3'-UTR	50.0%	50.0%
	16173	38	3'-UTR	91.0%	9.0%
20	16174	39	3'-UTR	136.0%	---
	16175	40	3'-UTR	69.0%	31.0%
	16176	41	3'-UTR	130.0%	---
	16177	42	3'-UTR	94.0%	6.0%
	16178	43	3'-UTR	55.0%	45.0%
25	16179	44	3'-UTR	48.0%	52.0%

**EXAMPLE 4****Human Fap-1 Oligonucleotide Sequences**

Antisense oligonucleotides were designed to target  
human Fap-1. Target sequence data are from the protein  
30 tyrosine phosphatase (PTP-BAS, type 1) cDNA sequence

published by Maekawa, K. et al. (*FEBS Lett.*, **1994**, 337, 200-206); Genbank accession number D21209, provided herein as SEQ ID NO: 45. Oligonucleotides were synthesized as chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five nucleotide "wings." The wings are composed of 2'-methoxyethyl (2'MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All 2'-MOE cytosines and 2'-deoxy cytosines were 5-methyl-cytosines. These oligonucleotide sequences are shown in Table 6.

C8161 cells were grown and treated with oligonucleotide as described in Example 2 except that 9 ?g/ml LIPOFECTIN<sup>7</sup> was used. mRNA was isolated and quantitated as described in Example 2. Results are shown in Table 7. Oligonucleotides 16148 (SEQ ID NO. 48), 18470 (SEQ ID NO. 50), 18471 (SEQ ID NO. 51), 18472 (SEQ ID NO. 52), 18473 (SEQ ID NO. 53), 18479 (SEQ ID NO. 58), 18480 (SEQ ID NO. 59), 18481 (SEQ ID NO. 60), and 18485 (SEQ ID NO. 64) resulted in greater than 60% inhibition of Fap-1 mRNA expression in this assay. Oligonucleotide 18479 (SEQ ID NO. 58) resulted in greater than 85% inhibition.

TABLE 6

25 **Nucleotide Sequences of Human FAP-1 Chimeric (deoxy gapped)**  
**Phosphorothioate Oligonucleotides**

ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
18467	ACGTGCATATTACCGGCTGG	47	0052-0071	AUG
18468	GAGAAATGATGAAGCCAAGG	48	0201-0220	coding

	18469	<b>GTTGGCTCTGAGGCACTTCA</b>	49	0405-0424	coding
	18470	<b>TTTGTCTCTCTCGGATTCGG</b>	50	1200-1219	coding
	18471	<b>GCCAAAGAAATTCCTCAGTT</b>	51	1664-1683	coding
	18472	<b>AAGGATGCCAGCAATAAGGA</b>	52	2158-2177	coding
5	18473	<b>GGTCTTCAATGGATGAGGAG</b>	53	3189-3208	coding
	18474	<b>GTGGTGATCCTTGGAAGAAG</b>	54	3701-3720	coding
	18475	<b>TCCACTCCCACTGCTGTCAC</b>	55	5021-5040	coding
	18476	<b>TTCTCTGATTGCCTTTGGTT</b>	56	5472-5491	coding
	18478	<b>GCAACTCATCATTTCCCCAT</b>	57	6513-6532	coding
10	18479	<b>CCAGAGGCTCTTTTCATGTC</b>	58	7520-7539	stop
	18480	<b>GCATCCAGAGGCTCTTTTCA</b>	59	7524-7543	3'-UTR
	18481	<b>GCTGGAGGTTAAGGAGAGAA</b>	60	7552-7571	3'-UTR
	18482	<b>TTTGGATAGAGAGCAGGAGT</b>	61	7574-7593	3'-UTR
	18483	<b>TTTCAAGAAGAATACCCCTA</b>	62	7648-7667	3'-UTR
15	18484	<b>GCTGCCTTTAATCATCCCTA</b>	63	7760-7779	3'-UTR
	18485	<b>ACTGGTTTCAAGTATCCCCT</b>	64	7891-7910	3'-UTR

<sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues, 2'-methoxyethoxy cytosine residues and 2'-OH cytosine residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

<sup>2</sup> Coordinates from Genbank Accession No. D21209, locus name "HUMPTPB1", SEQ ID NO. 45.

TABLE 7

Inhibition of Human Fap-1 mRNA expression in C8161 Cells by Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides

ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
control	---	---	100.0%	0.0%
18468	48	coding	33.4%	66.6%

	ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
	18469	49	coding	71.9%	28.1%
	18470	50	coding	33.2%	66.8%
	18471	51	coding	33.3%	66.7%
	18472	52	coding	26.9%	73.1%
5	18473	53	coding	28.3%	71.7%
	18474	54	coding	51.9%	48.1%
	18475	55	coding	46.2%	53.8%
	18476	56	coding	133.6%	---
	18479	58	stop	11.6%	88.4%
10	18480	59	3'-UTR	30.8%	69.2%
	18481	60	3'-UTR	35.2%	64.8%
	18482	61	3'-UTR	55.0%	45.0%
	18483	62	3'-UTR	55.3%	44.7%
	18485	64	3'-UTR	35.6%	64.4%

## 15 **EXAMPLE 5**

### **Mouse Fas Oligonucleotide Sequences**

Antisense oligonucleotides were designed to target mouse Fas. Target sequence data are from the Fas cDNA sequence published by Watanabe-Fukunaga, R. et al. (*J. Immunol.*, **1992**, 148, 1274-1297); Genbank accession number M83649, provided herein as SEQ ID NO: 65. Oligonucleotides were synthesized as chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'deoxy nucleotides, which is flanked on both sides (5' and 3' directions) by five nucleotide "wings." The wings are composed of 2'methoxyethyl (2'MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All 2'-MOE and 2'-OH cytosines were



5-methyl-cytosines. Oligonucleotide sequences are shown in Table 8.

AML12 cells, a murine hepatocyte cell line, was obtained from ATCC (Manassas, VA). AML12 cells were  
5 cultured in a 1:1 mixture of DMEM and F12 medium with 5.0  $\mu$ g/ml insulin, 5.0  $\mu$ g/ml transferrin, 5.0 NG/ml selenium, 0.04  $\mu$ g/ml dexamethasone and 10% FBS (all cell culture reagents available from Life Technologies).

AML12 cells were transfected with oligonucleotides as  
10 described in Example 2 for C8161 cells except oligonucleotide treatment was for six hours. For an initial screen, AML12 cells were transfected with 300 nM oligonucleotide and RNA collected 24 hours later.

Total cellular RNA was isolated using the RNEASY<sup>7</sup> kit  
15 (Qiagen, Santa Clarita, CA). RNase protection experiments were conducted using RIBOQUANT<sup>TM</sup> kits and the mAPO-2 Custom Probe Set set according to the manufacturer's instructions (Pharmingen, San Diego, CA). mRNA levels were quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

20 Results are shown in Table 9. Oligonucleotides 22017 (SEQ ID NO. 67), 22018 (SEQ ID NO. 68), 22019 (SEQ ID NO. 69), 22023 (SEQ ID NO. 73), 22024 (SEQ ID NO. 74), 22025 (SEQ ID NO. 75), 22026 (SEQ ID NO. 76), 22027 (SEQ ID NO. 77), 22028 (SEQ ID NO. 78), 22030 (SEQ ID NO. 80) and 22032  
25 (SEQ ID NO. 82) gave better than 40% inhibition of Fas mRNA in this assay. Oligonucleotides 22018 (SEQ ID NO. 68), 22023 (SEQ ID NO. 73), 22026 (SEQ ID NO. 76), 22028 (SEQ ID NO. 78), and 22030 (SEQ ID NO. 80) gave better than 60% inhibition of Fas mRNA.

TABLE 8

Nucleotide Sequences of Mouse Fas Chimeric (deoxy gapped)  
Phosphorothioate Oligonucleotides

	ISIS NO.	NUCLEOTIDE SEQUENCE <sup>1</sup> (5' -> 3')	SEQ ID NO:	TARGET GENE NUCLEOTIDE CO-ORDINATES <sup>2</sup>	GENE TARGET REGION
5	22017	GCAGCAAGGGAAAACAGCGG	67	0026-0045	5'-UTR
	22018	CCACAGCATGTCTGCAGCAA	68	0039-0058	AUG
	22019	TTTCATGAACCCGCCCTCCTC	69	0148-0167	coding
	22020	GGGTCAGGGTGCAGTTTGTT	70	0385-0404	coding
	22021	GAGGCGCAGCGAACACAGTG	71	0461-0480	coding
10	22022	CATAGGCGATTTCTGGGACT	72	0542-0561	coding
	22023	TCCAGCACTTTCTTTTCCGG	73	0616-0635	coding
	22024	GGTTTCACGACTGGAGGTTC	74	0663-0682	coding
	22025	CTTCAGCAATTCTCGGGATG	75	0721-0740	coding
	22026	GCCCTCCTTGATGTTATTTT	76	0777-0796	coding
15	22027	GGTACCAGCACAGGAGCAGC	77	0853-0872	coding
	22028	CGGCTTTTTTGAGACCCTTG	78	0910-0929	coding
	22029	GTGTCTGGGGTTGATTTTCC	79	0980-0999	coding
	22030	TCTCCTCTCTTCATGGCTGG	80	1048-1067	3'-UTR
	22031	GGCATTCATTTTGTTTCCAT	81	1084-1103	3'-UTR
20	22032	TCCCTGGAACCTGCTAGTCA	82	1180-1199	3'-UTR
	22033	TCAGCAACTGCAGAGAATAA	83	1209-1228	3'-UTR
	22034	GCAGATTCCACTTCACATTT	84	1290-1309	3'-UTR
	22035	AAGGTCTTCAATTAAGTGCG	85	1372-1391	3'-UTR

25 <sup>1</sup> Emboldened residues are 2'-methoxyethoxy residues, 2'-methoxyethoxy cytosine residues and 2'-OH cytosine residues are 5-methyl-cytosines; all linkages are phosphorothioate linkages.

<sup>2</sup> Coordinates from Genbank Accession No. M83649, locus name "MUSFASANT", SEQ ID NO. 65.

TABLE 9

Inhibition of Mouse Fas mRNA expression in AML12 Cells by  
5 Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides

ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
control	---	---	100%	0%
LIPOFECTIN <sup>7</sup>	---	---	136%	---
10 22017	67	5'-UTR	44%	56%
22018	68	AUG	38%	62%
22019	69	coding	56%	44%
22020	70	coding	69%	31%
22021	71	coding	77%	23%
15 22022	72	coding	77%	23%
22023	73	coding	37%	63%
22024	74	coding	49%	51%
22025	75	coding	57%	43%
22026	76	coding	31%	69%
20 22027	77	coding	53%	47%
22028	78	coding	28%	72%
22029	79	coding	82%	18%
22030	80	3'-UTR	22%	78%
22031	81	3'-UTR	76%	24%
25 22032	82	3'-UTR	47%	53%
22033	83	3'-UTR	103%	---
22034	84	3'-UTR	80%	20%
22035	85	3'-UTR	98%	2%

**EXAMPLE 6**

**Dose response of antisense chimeric (deoxy gapped) phosphorothioate oligonucleotide effects on mouse Fas mRNA levels in AML12 cells**

5 Oligonucleotides 22019 (SEQ ID. NO. 69), 22023 (SEQ ID. NO. 73) and 22028 (SEQ ID. NO. 78) was chosen for a dose response study. AML12 cells were grown, treated and processed as described in Example 5.

Results are shown in Table 10. IC<sub>50</sub>s were 150 nM or  
10 less and maximal inhibition seen was greater than 80%.

**TABLE 10**

**Dose Response of AML12 cells to Fas  
Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides**

	SEQ ID	ASO Gene		% mRNA	% mRNA
ISIS #	NO:	Target	Dose	Expression	Inhibition
15 control	---	---	---	100%	---
22019	69	coding	75 nM	60%	40%
"	"	"	150 nM	53%	47%
"	"	"	300 nM	34%	66%
"	"	"	500 nM	14%	86%
20 22023	73	coding	75 nM	61%	39%
"	"	"	150 nM	28%	72%
"	"	"	300 nM	22%	78%
"	"	"	500 nM	20%	80%
25 22028	78	coding	75 nM	57%	43%
"	"	"	150 nM	49%	51%
"	"	"	300 nM	42%	58%
"	"	"	500 nM	45%	55%

A similar experiment was performed which included mismatch control oligonucleotides (2, 4, 6 or 8 base mismatches). None of these control oligonucleotides inhibited Fas mRNA expression.

## 5 EXAMPLE 7

### **Inhibition of Fas expression in Balb/c Mice by Fas antisense chimeric (deoxy gapped) phosphorothioate oligonucleotides**

Balb/c mice were used to assess the activity of Fas antisense oligonucleotides. Female Balb/c mice, 8 to 10 weeks old, were intra peritoneally injected with oligonucleotide at 100 mg/kg mouse body weight. Mice were injected daily for four days. Control mice were injected with a saline solution. After the fourth day, the livers were removed from the animals and analyzed for Fas mRNA expression. RNA was extracted using the RNEASY<sup>7</sup> kit (Qiagen, Santa Clarita, CA) and quantitated using RPA as described in Example 5.

Results are shown in Table 11. Maximal inhibition seen in this assay was 80%.

**TABLE 11**

**Inhibition of Mouse Fas mRNA expression in Balb/c Mice by Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides**

ISIS No:	SEQ ID NO:	GENE TARGET REGION	% mRNA EXPRESSION	% mRNA INHIBITION
control	---	---	100%	0%
22019	69	coding	40%	60%
22023	73	coding	20%	80%
22028	78	coding	21%	79%

A dose response experiment was performed in Balb/c mice using oligonucleotides 22023 (SEQ ID NO. 73) and 22028 (SEQ ID NO. 78). Mice were treated as described above except the concentration of oligonucleotide was varied as shown in Table 12. Results are shown in Table 12. IC<sub>50</sub>s for these oligonucleotides is estimated to be about 9 mg/kg. Maximal inhibition seen was greater than 90%.

TABLE 12

## Dose Response of Balb/c to Fas

## 10 Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides

ISIS #	SEQ ID NO:	ASO Gene Target	Dose	% mRNA Expression	% mRNA Inhibition
control	---	---	---	100%	---
22023	73	coding	6 mg/kg	66%	34%
"	"	"	12 mg/kg	40%	60%
15	"	"	25 mg/kg	26%	74%
"	"	"	50 mg/kg	8%	92%
"	"	"	100 mg/kg	6%	94%
22028	78	coding	6 mg/kg	65%	35%
"	"	"	12 mg/kg	40%	60%
20	"	"	25 mg/kg	17%	83%
"	"	"	50 mg/kg	12%	88%
"	"	"	100 mg/kg	13%	87%

Oligonucleotide 22023 (SEQ ID NO. 73) was chosen for a time course study. Balb/c mice were treated as described above except that doses of 6 mg/kg and 12 mg/kg were used and treatment time (in days) was varied as shown in Table 13.

Results are shown in Table 13. Increasing the treatment time, in general, gave better results.

TABLE 13

Time Course of Balb/c to Fas Chimeric (deoxy gapped)  
Phosphorothioate Oligonucleotide

5

10

15

ISIS #	SEQ ID NO:	ASO Gene Target	Dose	Treatment Time	% mRNA Inhibition
control	---	---	---	---	---
22023	73	coding	6 mg/kg	2 d	54%
"	"	"	"	4 d	55%
"	"	"	"	7 d	84%
"	"	"	"	12 d	87%
22023	73	coding	12 mg/kg	2 d	40%
"	"	"	"	4 d	79%
"	"	"	"	7 d	92%
"	"	"	"	12 d	82%

The effect of oligonucleotides 22023 (SEQ ID NO. 69) and 22028 (SEQ ID NO. 78) on Fas protein expression was examined. Balb/c mice were injected with oligonucleotide as described above. Lpr mice (Jackson Laboratory, Bar Harbor, ME), a Fas knockout strain, were used as a control. Four hours after the last dose, the mice were sacrificed and a piece of liver was frozen in O.C.T. compound (Sakura Finetek USA, Inc., Torrance, CA). The liver was fixed for 1 minute in acetone, then stained with Fas antibody (rabbit anti rat/mouse fas, Research Diagnostics, Inc., Flanders, NJ) at 0.7 µg/ml for 45 minutes. A second antibody (HRP conjugated donkey anti-rabbit, Jackson Laboratory) was then added at 1:100 dilution for 30 minutes. Then DAB (DAKO Corporation, Carpinteria, CA) was added for color development. Tissue sections were visualized under a microscope.

Treatment with Fas antisense oligonucleotides reduced Fas protein expression to levels similar to those in Lpr mice.

#### **EXAMPLE 8**

##### **5 Effect of Fas Antisense Oligonucleotides in a Con A Murine Model for Hepatitis**

Concanavalin A-induced hepatitis is used as a murine model for autoimmune hepatitis (Mizuhara, H., et al., J. Exp. Med., **1994**, 179, 1529-1537). It has been shown that  
10 this type of liver injury is mediated by Fas (Seino, K., et al., Gastroenterology **1997**, 113, 1315-1322). Certain types of viral hepatitis, including Hepatitis C, are also mediated by Fas (*J. Gastroenterology and Hepatology*, **1997**, 12, S223-S226). Female Balb/c between the ages of 6 weeks  
15 and 3 months were used to assess the activity of Fas antisense oligonucleotides. For determining the effect of Fas antisense oligonucleotides on Fas mRNA expression, mice were injected intra peritoneally with oligonucleotide 22023 (SEQ ID NO. 73) at 50 mg/kg or 100 mg/kg, daily for 4 days.  
20 The pretreated mice were then intravenously injected with 0.3 mg concanavalin A (Con A) to induce liver injury. Within 24 hours following Con A injection, the livers were removed from the animals and RNA isolated using the RNEASY<sup>7</sup> kit (Qiagen, Santa Clarita, CA) and quantitated using RPA  
25 as described in Example 5.

Results are shown in Table 14.



TABLE 14

Reduction of Balb/c Liver Fas mRNA with Fas Antisense  
Chimeric (deoxy gapped) Phosphorothioate Oligonucleotide  
following ConA treatment

5 ISIS #	SEQ ID	ASO Gene		% mRNA	% mRNA
	NO:	Target	Dose	Expression	Inhibition
control	---	---	---	100%	---
22023	73	coding	50 mg/kg	16%	84%
"	"	"	100 mg/kg	18%	82%

**EXAMPLE 9**

10 **Effect of Fas Antisense Oligonucleotides in a Fas Cross-  
linking Antibody Murine Model for Hepatitis**

Injection of agonistic Fas-specific antibody into mice can induce massive hepatocyte apoptosis and liver hemorrhage, and death from acute hepatic failure

15 (Ogasawara, J., et al., *Nature*, **1993**, 364, 806-809).

Apoptosis-mediated aberrant cell death has been shown to play an important role in a number of human diseases. For example, in hepatitis, Fas and Fas ligand up-regulated expression are correlated with liver damage and apoptosis.

20 It is thought that apoptosis in the livers of patients with fulminant hepatitis, acute and chronic viral hepatitis, autoimmune hepatitis, as well as chemical or drug induced liver intoxication may result from Fas activation on hepatocytes.

25 Eight to ten week-old female Balb/c mice were intra peritoneally injected with oligonucleotides 22023 (SEQ ID NO. 73) and 22028 (SEQ ID NO. 78) at 50 mg/kg, daily for 4 days. Four hours after the last dose, 7.5  $\mu$ g of mouse Fas antibody (Pharmingen, San Diego, CA) was injected into the

mice. Mortality of the mice was measured for more than 10 days following antibody treatment.

Results are shown in Table 15. Mortality is expressed as a fraction where the denominator is the total number of mice used and the numerator is the number that died.

**TABLE 15**

**Protective Effects of Fas Antisense Chimeric (deoxy gapped) Phosphorothioate Oligonucleotides in Fas Antibody Cross-linking Induced Death in Balb/c Mice**

ISIS #	SEQ ID NO:	ASO Gene Target	Dose	Mortality
saline	---	---	---	6/6
22023	73	coding	50 mg/kg	0/6
22028	78	coding	50 mg/kg	0/6

15 Oligonucleotides 22023 (SEQ ID NO. 73) and 22028 (SEQ ID NO. 78) completely protected the Fas antibody treated mice from death. Mice injected with saline or scrambled control oligonucleotide did not confer any protective effect.

20 Total RNA was extracted from the livers of Fas antibody treated mice using the RNEASY<sup>7</sup> kit (Qiagen, Santa Clarita, CA). Fas mRNA expression was quantitated using RPA as described in Example 5. It was found that high levels of Fas mRNA expression in this model correlated with increased mortality of Fas antibody treated mice.

**EXAMPLE 10****Oligonucleotide Synthesis - 96 Well Plate Format**

In accordance with the present invention additional oligonucleotides targeting human Fas were designed and  
5 screened in a 96 well plate format.

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format.

10 Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-  
15 protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g., PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base  
20 protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in  
25 sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

**EXAMPLE 11****Oligonucleotide Analysis - 96 Well Plate Format**

30 The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in

either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds  
5 utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

## 10 **EXAMPLE 12**

### **Cell culture and oligonucleotide treatment-96 Well Plate Format**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell  
15 types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 5 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the  
20 target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

#### T-24 cells:

25 The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented  
30 with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life

Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

10 A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium

(Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

5 HepG2 cells:

The human hepatoblastoma cell line HepG2 was obtained from the American Type Culture Collection (Manassas, VA). HepG2 cells were routinely cultured in Eagle's MEM supplemented with 10% fetal calf serum, non-essential amino  
10 acids, and 1 mM sodium pyruvate (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in  
15 RT-PCR analysis.

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

20 Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130  $\mu$ L of  
25 OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

30 The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line,

the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 86, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 87, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

### EXAMPLE 13

#### 25 **Analysis of oligonucleotide inhibition of Fas expression-96** **Well Plate Format**

Antisense modulation of Fas expression can be assayed in a variety of ways known in the art. For example, Fas mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA

isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., **1993**. Northern blot analysis is routine in the art and is taught  
5 in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., **1996**. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from  
10 PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of Fas can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or  
15 fluorescence-activated cell sorting (FACS). Antibodies directed to Fas can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for  
20 preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., **1997**. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al.,  
25 *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., **1997**.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp.  
30 10.16.1-10.16.11, John Wiley & Sons, Inc., **1998**. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-



10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-  
5 11.2.22, John Wiley & Sons, Inc., 1991.

#### EXAMPLE 14

##### Poly(A)+ mRNA isolation - 96 Well Plate Format

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for  
10 poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was  
15 washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was  
20 transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove  
25 excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.  
30 Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

**EXAMPLE 15****Total RNA Isolation- 96 Well Plate Format**

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 µL cold PBS. 100 µL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 µL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 µL water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

**EXAMPLE 16****Real-time Quantitative PCR Analysis of Fas mRNA Levels-96  
Well Plate Format**

Quantitation of Fas mRNA levels was determined by  
5 real-time quantitative PCR using the ABI PRISM™ 7700  
Sequence Detection System (PE-Applied Biosystems, Foster  
City, CA) according to manufacturer's instructions. This  
is a closed-tube, non-gel-based, fluorescence detection  
system which allows high-throughput quantitation of  
10 polymerase chain reaction (PCR) products in real-time. As  
opposed to standard PCR, in which amplification products  
are quantitated after the PCR is completed, products in  
real-time quantitative PCR are quantitated as they  
accumulate. This is accomplished by including in the PCR  
15 reaction an oligonucleotide probe that anneals specifically  
between the forward and reverse PCR primers, and contains  
two fluorescent dyes. A reporter dye (e.g., JOE, FAM, or  
VIC, obtained from either Operon Technologies Inc.,  
Alameda, CA or PE-Applied Biosystems, Foster City, CA) is  
20 attached to the 5' end of the probe and a quencher dye  
(e.g., TAMRA, obtained from either Operon Technologies  
Inc., Alameda, CA, or PE-Applied Biosystems, Foster City,  
CA) is attached to the 3' end of the probe. When the probe  
and dyes are intact, reporter dye emission is quenched by  
25 the proximity of the 3' quencher dye. During  
amplification, annealing of the probe to the target  
sequence creates a substrate that can be cleaved by the 5'-  
exonuclease activity of Taq polymerase. During the  
extension phase of the PCR amplification cycle, cleavage of  
30 the probe by Taq polymerase releases the reporter dye from  
the remainder of the probe (and hence from the quencher  
moiety) and a sequence-specific fluorescent signal is  
generated. With each cycle, additional reporter dye  
molecules are cleaved from their respective probes, and the

fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 µL PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM MgCl<sub>2</sub>, 300 µM each of dATP, dCTP and dGTP, 600 µM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 µL total RNA solution. The RT reaction was

carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al., *Analytical Biochemistry*, **1998**, 265, 368-374.

In this assay, 175 µL of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:2865 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 25uL purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human Fas were designed to hybridize to a human Fas sequence, using published sequence information (GenBank accession number X63717, incorporated herein as SEQ ID NO: 1). For human Fas the PCR primers were: forward primer: TCATGACACTAAGTCAAGTTAAAGGCTTT (SEQ ID NO: 88) reverse primer: TCTTGACATTGTCATTCTTGATCTC (SEQ ID NO: 89) and the PCR probe was: FAM-ATTTTGGCTTCATTGACACCATTCTTTTCGAA-TAMRA (SEQ ID NO: 90) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were: forward primer: CAACGGATTTGGTCGTATTGG (SEQ ID NO: 91) reverse primer: GGCAACAATATCCACTTTACCAGAGT

(SEQ ID NO: 92) and the PCR probe was: 5' JOE-CGCCTGGTCACCAGGGCTGCT- TAMRA 3' (SEQ ID NO: 93) where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

#### **EXAMPLE 17**

##### **Northern blot analysis of Fas mRNA levels-96 Well Plate**

##### **Format**

Eighteen hours after antisense treatment, cell  
10 monolayers were washed twice with cold PBS and lysed in 1  
mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA  
was prepared following manufacturer's recommended  
protocols. Twenty micrograms of total RNA was fractionated  
by electrophoresis through 1.2% agarose gels containing  
15 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc.  
Solon, OH). RNA was transferred from the gel to HYBOND™-N+  
nylon membranes (Amersham Pharmacia Biotech, Piscataway,  
NJ) by overnight capillary transfer using a Northern/  
Southern Transfer buffer system (TEL-TEST "B" Inc.,  
20 Friendswood, TX). RNA transfer was confirmed by UV  
visualization. Membranes were fixed by UV cross-linking  
using a STRATALINKER™ UV Crosslinker 2400 (Stratagene,  
Inc, La Jolla, CA) and then robed using QUICKHYB™  
hybridization solution (Stratagene, La Jolla, CA) using  
25 manufacturer's recommendations for stringent conditions.

To detect human Fas, a human Fas specific probe was  
prepared by PCR using the forward primer  
TCATGACACTAAGTCAAGTTAAAGGCTTT (SEQ ID NO: 88) and the  
reverse primer TCTTGGACATTGTCATTCTTGATCTC (SEQ ID NO: 89).  
30 To normalize for variations in loading and transfer  
efficiency membranes were stripped and probed for human  
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA  
(Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

## 5 EXAMPLE 18

### **Antisense inhibition of human Fas expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap-96 Well Plate Format**

In accordance with the present invention, a series of  
10 oligonucleotides were designed to target different regions of the human Fas RNA, using published sequences (GenBank accession number X63717, incorporated herein as SEQ ID NO: 1, GenBank accession number D31968, incorporated herein as SEQ ID NO: 94, GenBank accession number X81336,  
15 incorporated herein as SEQ ID NO: 95, GenBank accession number X81337, incorporated herein as SEQ ID NO: 96, GenBank accession number X81338, incorporated herein as SEQ ID NO: 97, GenBank accession number X81339, incorporated herein as SEQ ID NO: 98, GenBank accession number X81340,  
20 incorporated herein as SEQ ID NO: 99, GenBank accession number X81341, incorporated herein as SEQ ID NO: 100, GenBank accession number X81342, incorporated herein as SEQ ID NO: 101, and GenBank accession number Z70520, incorporated herein as SEQ ID NO: 102). The  
25 oligonucleotides are shown in Table 16. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 16 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length,  
30 composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The

internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human Fas mRNA levels by quantitative real-time PCR as described in other examples herein. ISIS 119513 and ISIS 17020 have the same nucleotide base sequence and differ only in that the cytidine residues are 5-methylcytidines in ISIS 119513. These two oligonucleotides are therefore both labeled SEQ. ID. NO: 11. Data are averages from two experiments. If present, "N.D." indicates "no data".

TABLE 16

Inhibition of human Fas mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
119485	5'UTR	94	1398	tgaggaaggagtcagggttc	0	103
119486	5'UTR	94	1510	ggtggtcaggaggatgggaa	0	104
119487	Intron	94	1949	agccagtctccaacgcctcc	30	105
119488	Intron	94	2058	tgccccgcctgccagcgagg	31	106
119489	5'UTR	1	2	acacctgtgtgtcactcttg	36	107
119490	5'UTR	1	51	gccaaagtcactcgtaaaccg	27	108
119491	5'UTR	1	190	aatcctccgaagtgaagag	43	109
119492	Start Codon	1	212	atgccagcatggttggtga	38	110
119493	Coding	1	241	acgtaagaaccagaggtagg	51	111
119494	Coding	1	265	ttttggacgataatctagca	63	112
119495	Coding	1	407	ttcctttcacctggaggaca	53	113
119496	Coding	1	419	cagtccctagctttcctttc	36	114
119497	Coding	1	538	agccatgtccttcatcacac	71	115
119498	Coding	1	635	gggtcacagtgttcacatac	52	116
119499	Coding	1	687	gttgctggtgagtgtgcatt	37	117
119500	Coding	1	785	acttcctttctcttcaccca	0	118
119501	Coding	1	821	tggttttcctttctgtgctt	60	119
119502	Coding	1	848	tttaagggttgagattcatg	22	120
119503	Coding	1	850	gatttaagggttgagattca	3	121
119504	Coding	1	862	ccactgtttcaggatttaag	14	122
119505	Coding	1	885	gtcaacatcagataaattta	26	123
119506	Coding	1	894	tttactcaagtcaacatcag	52	124
119507	Coding	1	928	ttagtgtcatgactccagca	67	125
119508	Coding	1	936	aacttgacttaagtgtcatga	31	126



5	119509	Coding	1	1039	tacgaagcagttgaactttc	51	127
	119510	Coding	1	1097	ttgagatctttaataatcaatgt	60	128
	119511	Coding	1	1152	gtccttgaggatgatagtct	44	129
	119512	Coding	1	1197	ttggatttcatttctgaagt	37	130
	119513	Stop Codon	1	1214	tcactctagaccaagctttg	66	11
10	119514	Stop Codon	1	1218	tttttcactctagaccaagc	37	131
	119515	3'UTR	1	1291	aagcagtattttacagccagc	80	132
	119516	3'UTR	1	1331	tcagcgctaataaatgataa	54	133
	119517	3'UTR	1	1335	ctcttcagcgctaataaatg	72	134
	119518	3'UTR	1	1437	atgccactgcatttactctt	34	135
15	119519	3'UTR	1	1438	catgccactgcatttactct	49	136
	119520	3'UTR	1	1525	acattcatactacagaatca	52	137
	119521	3'UTR	1	1537	catacactgattacattcat	17	138
	119522	3'UTR	1	1726	ttacataaatatgatcttct	32	139
	119523	3'UTR	1	1769	gaggtagagccttattttaa	69	140
20	119524	3'UTR	1	1806	gtataaatatgacaccaataa	75	141
	119525	3'UTR	1	1812	aattattgtataaatatgacac	15	142
	119526	3'UTR	1	1828	gtgaattcaccaattgaaata	39	143
	119527	3'UTR	1	1850	attataattttaatgttttct	0	144
	119528	3'UTR	1	1940	tactctcctgctcaaaatgc	18	145
25	119529	3'UTR	1	2047	tgggtggactattaagtattt	67	146
	119530	3'UTR	1	2102	agagcagtttagtatctccaa	78	147
	119531	3'UTR	1	2119	caaagctactttctctgaga	62	148
	119532	3'UTR	1	2128	gacatgtcacaaagctactt	41	149
	119533	3'UTR	1	2159	ttatcatctttgattgcaaa	63	150
30	119534	3'UTR	1	2210	atgggacattattgaacatt	57	151
	119535	3'UTR	1	2371	attcacattttaatacaaaact	0	152
	119536	3'UTR	1	2392	atataaatattatttcttaa	14	153
	119537	3'UTR	95	361	ctatgtgctactcctaactg	66	154
	119538	3'UTR	95	367	tgattactatgtgctactcc	45	155
35	119539	3'UTR	95	469	tataaataaaaactcatcttt	0	156
	119540	3'UTR	96	384	cttcccttttctgtgtgtca	50	157
	119541	3'UTR	96	401	taccctagccacctgtcctt	12	158
	119542	3'UTR	96	470	ctggaagaattgcctagact	39	159
	119543	3'UTR	96	492	atatttactcatttctcctat	10	160
40	119544	3'UTR	96	808	atgtccagagggtttcttcat	54	161
	119545	3'UTR	96	851	agaaacattgctttataggc	61	162
	119546	5'UTR	97	7	atgacaccagtaatacagtc	58	163
	119547	5'UTR	97	41	tttgagatccactgcttata	7	164
	119548	5'UTR	97	114	gtttggaaactattagttat	15	165
45	119549	Intron	98	33	atgtgtgatttccttcagac	49	166
	119550	Intron	98	338	atcataaggaatgactgtct	46	167
	119551	Intron	98	470	aatggcactttgtaaattag	50	168
	119552	Intron	98	480	tataattttcaatggcactt	15	169
	119553	Intron	98	494	cagaataattcctttataat	16	170
50	119554	Coding	98	543	ccatgttcacatctagaaaa	30	171
	119555	Start Codon	99	67	tctcttcactgaagaacaa	17	172
	119556	3'UTR	99	172	aggaaaagctgatacctat	47	173
	119557	3'UTR	100	293	catctctatgaaataaaatg	3	174
	119558	3'UTR	100	504	ggaaaagtttcttaagcctc	60	175
50	119559	3'UTR	100	656	ttatctctaaatcacagatc	57	176
	119560	3'UTR	101	1759	aaagagaaaaccagaaatac	0	177

119561	3'UTR	101	1804	gttagagaaaaggaagacaa	56	178
119562	Coding	102	325	atgttcacatcatgtccttc	5	179

As shown in Table 16, SEQ ID NOs 11, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 119, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 139, 140, 141, 143, 146, 147, 148, 149, 150, 151, 154, 155, 157, 159, 161, 162, 163, 166, 167, 168, 171, 173, 175, 176 and 178 demonstrated at least 25% inhibition of human Fas expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "active sites" and are therefore preferred sites for targeting by compounds of the present invention.

#### EXAMPLE 19

##### 15 Western blot analysis of Fas protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 hours after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Fas is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

#### EXAMPLE 20

##### Effect of Fas Antisense Oligonucleotides in a Murine Model of Renal Ischemia-Reperfusion Injury

30 Ischemia-reperfusion can result in organ failure with the severity of damage being proportional to the duration

of ischemia. In the kidney, the damage has been partially attributed to apoptosis in tubular cells. It has been demonstrated that Fas mRNA expression is upregulated in kidneys suffering from ischemia-reperfusion injury. Mice lacking Fas (lpr mice) undergo significantly less apoptosis and it is therefore believed that the apoptotic response to ischemia-reperfusion involves the Fas/FasL signaling pathway. Consequently, inhibition of Fas might serve to attenuate organ injury in the kidney after ischemia-reperfusion.

The antisense oligonucleotide ISIS 22023 (SEQ ID NO: 73) and an 8-base mismatch control oligonucleotide (ISIS 29837; SEQ ID NO: 180) were used in studies to determine the effects of systemic administration of anti-Fas antisense oligonucleotides on renal ischemia-reperfusion injury.

Male C57BL/10 (B10) mice (10 to 12 weeks old purchased from The Jackson Laboratory) were injected intraperitoneally with ISIS 22023 or the control oligonucleotide at 25-100 mg/day for five days. Following the treatment protocol, the left renal artery and vein were clamped for 30, 60 or 90 minutes followed by reperfusion for 24 hours. Serum was collected and both kidneys were removed. The right kidneys were used as controls. Reperfusion damage was determined by histological examination. Apoptosis and DNA fragmentation in the renal cells was identified by *in situ* TdT-mediated dUTP nick end labeling (TUNEL) staining and agarose-gel electrophoresis. Methods of detecting DNA fragmentation by TUNEL analysis is well known in the art. Briefly, the cleavage of cellular DNA into low molecular weight fragments, which occurs in the early stages of apoptosis, is detected by labeling the free 3'-OH termini of the fragments with modified nucleotides. These nucleotides usually contain a

chromophore or fluorescent detectible group and are added by the enzyme, terminal deoxynucleotidyl transferase (TdT) to the blunt ends of DNA fragments. Cells are then analyzed for the presence of the chromophore using standard  
5 electrophoresis and imaging techniques. Cells undergoing apoptosis are considered TUNEL-positive.

Expression of Fas was determined by immunohistochemical staining and Western blotting using antibodies specific for Fas. Serum BUN and creatinine were  
10 also measured in a sub-group of mice that underwent clamping of both renal arteries.

Histological examination revealed that histological damage caused by ischemia-reperfusion was significantly reduced by administration of the Fas antisense  
15 oligonucleotide at doses higher than 50 mg/day including attenuated tubule cell detachment and cast formation.

Immunohistochemistry revealed that normal kidneys expressed Fas, particularly in the tubule areas, but few cells were TUNEL positive. This is believed to indicate  
20 that the renal tubule cells are vulnerable to Fas-mediated apoptosis.

Ischemia longer than 60 minutes significantly enhanced Fas expression and apoptotic activity in tubular cells, both of which were significantly inhibited by systemic  
25 administration of ISIS 22023.

TUNEL positive cells reached up to 51.7 +/- 4.9 hpf in kidneys that were ischemic for 90 minutes (compared with 0 hpf in normal kidneys), while only 9.3 +/- 1.7 positive cells were identified in animals that were treated with  
30 ISIS 22023 at 50 mg/day.

Taken together these data suggest that inhibition of Fas expression and apoptotic activity in ischemic kidneys by systemic treatment with antisense oligonucleotide administration is a potential therapeutic approach as well  
5 as being a convenient mode of delivery.